Immitra Bio raises CHF 2.4M for in-vivo gene editing, led by Backbone Ventures with OCCIDENT. Funding will support preclinical studies for a one-time treatment for inherited anemia.
Amount Raised
CHF2.4 Million
Round Type
Pre-Seed
ZurichBiotechnologyHealth CareTherapeuticsInvestors
Description
Immitra Bio has secured CHF 2.4M to advance its in-vivo gene editing technology. The funding will primarily be used for preclinical proof-of-concept studies for its potential treatment, IB-003. Backbone Ventures led the round, with several other investors participating. The company aims to simplify gene-edited therapies and bring forth a mutation-agnostic treatment.
Quick answer
Immitra Bio raised CHF2.4 Million in a Pre-Seed round, dated July 21, 2026. Investors: Kickfund, Occident, Eth Foundation, Venture Kick, Zürcher Kantonalbank, Fongit and Backbone Ventures. Immitra Bio is based in Zurich, Zurich, Switzerland.
- How much did Immitra Bio raise?
- Immitra Bio raised CHF2.4 Million in a Pre-Seed round on July 21, 2026.
- Who invested in Immitra Bio?
- Kickfund, Occident, Eth Foundation, Venture Kick, Zürcher Kantonalbank, Fongit and Backbone Ventures are named as investors in this round.
- What does Immitra Bio do?
- Immitra Bio is a biotechnology company focused on developing innovative gene editing therapies.
- Where is Immitra Bio based and how big is it?
- Immitra Bio is based in Zurich, Zurich, Switzerland. Fundz records about 4 employees.
- Who are the decision-makers at Immitra Bio?
- Fundz holds 2 contacts at Immitra Bio, including the CEO and Co-Founder. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Immitra Bio that raised within 45 days of this round, from Fundz verified event records.
- Dimerix Limited raised $25M (Debt Financing) on September 4, 2026.
- ZoeNCure Therapeutics Pvt. Ltd raised $2.4M (Seed) on September 3, 2026.
- NovaGo Therapeutics AG raised $30M (Series B) on September 2, 2026.
- Typewriter Therapeutics raised $56M (Series A) on September 2, 2026.
- NovaGo Therapeutics raised $30M (Series B) on September 2, 2026.
- CytoDyn raised $17M on September 1, 2026.
Who to call at Immitra Bio, and when
A new round usually means Immitra Bio is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Immitra Bio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Immitra Bio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Immitra Bio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Immitra Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Immitra Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.